Insmed Inc (INSM)vsScholar Rock Holding Corp (SRRK)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
SRRK
Scholar Rock Holding Corp
$45.43
+7.40%
HEALTHCARE · Cap: $4.86B
Smart Verdict
WallStSmart Research — data-driven comparison
SRRK leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
SRRK
Avoid23
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : SRRK
SRRK has a balanced fundamental profile.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : SRRK
The primary concerns for SRRK are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while SRRK is a value play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
SRRK generates stronger free cash flow (-76M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 23/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Scholar Rock Holding Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Scholar Rock Holding Corporation, a clinical-phase biopharmaceutical company, is focused on the discovery and development of drugs for the treatment of serious diseases in which protein growth factor signaling plays a critical role. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?